Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAtla, Inc. - Common Stock (NQ:BCAB)

3.330 -0.590 (-15.05%)
Streaming Delayed Price Updated: 10:27 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioAtla, Inc. - Common Stock

News headline image
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the Jefferies London Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
Award recognizes Dr. Short’s contribution to science innovation 
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in Upcoming Investor Conferences in August
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the Jefferies Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the JMP Securities Life Sciences Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Announces Change in Executive Leadership
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Participate in the Jefferies London Healthcare Conference
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
From BioAtla, Inc.
Via GlobeNewswire
News headline image
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
From BioAtla, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.